Skip to main content Accessibility help
×
Home

Ethics in Canadian health technology assessment: A descriptive review

  • Deirdre DeJean (a1), Mita Giacomini (a1), Lisa Schwartz (a1) and Fiona A. Miller (a2)

Abstract

Background: Despite the mandate to examine the medical, ethical, and economic implications of the development and use of health technology, health technology assessment (HTA) reports often emphasize the epidemiologic and economic aspects, and omit ethical considerations. This study examines both whether and how ethical issues are incorporated into HTA.

Objectives: We aim to (i) review a set of Canadian HTA reports for ethics content, (ii) describe the strategies used to incorporate ethically relevant information into HTA, and (iii) determine the presence of implicit ethical issues in a sample of HTA reports.

Methods: Descriptive and qualitative content analysis of 608 HTA reports produced by six Canadian HTA agencies from January 1997 to December 2006.

Results: We found that (i) a minority (17 percent) of Canadian HTA reports addressed ethical issues, (ii) secondary research predominates while primary analysis is rare, (iii) implicit ethical issues are present in HTA reports that do not purport to address ethics.

Conclusions: Canadian HTA reports rarely explicitly, and then only superficially, address ethics, though implicit ethical issues abound.

Copyright

References

Hide All
1. Ashcroft, R. Health technology assessment. In: The concise encyclopedia of the ethics of new technologies. San Diego: Academic Press; 2001:235244.
2. Banta, H, Perry, S. A history of ISTAHC. A personal perspective on its first 10 years. International Society of Technology Assessment in Health Care. Int J Technol Assess Health Care. 1997;13:430453.
3. Beauchamp, TL. Principles of biomedical ethics. 5th ed. Oxford: Oxford University Press; 2001.
4. Benatar, D. Bioethics and health and human rights: A critical view. J Med Ethics. 2006;32:1720.
5. Boothroyd, L, Lehoux, P. Home-based chemotherapy for cancer: Issues for patients, caregivers and the health care system. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2004.
6. Brophy, J, Erickson, L. An economic analysis of drug eluting coronary stents: A Quebec perspective. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2004.
7. Brown, A, Coyle, D, Chen, S, Cumming, D, Mensinkai, S. Transdermal hormone replacement therapy patches for women with postmenopausal symptoms: Economic analysis of short-term use. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2006.
8. Busse, R, Velasco, M, Perleth, M, et al. Best practice in undertaking and reporting health technology assessments. Working group 4 report. Int J Technol Assess Health Care. 2002;18:361422.
9. Callahan, D. Principlism and communitarianism. J Med Ethics. 2003;29:287291.
10. Dahlgren, H. Ethics: Not a mirron parameter for HTA or how could we better integrate ethics into HTA? In: The 6th Symposium on Health Technology Assessment: Cologne; 2005.
11. Davies, C, Wetherell, M, Barnett, E, Seymour-Smith, S. Opening the box: Evaluating the citizens council of NICE. Bristol: The Open University; 2005.
12. Demeter, S, Hailey, D. Non-penetrating glaucoma surgery using AquaFlow(TM) collagen implants. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA); 2001.
13. Draborg, E, Andersen, CK. What influences the choice of assessment methods in health technology assessments? Atatistical analysis of international health technology assessments from 1989 to 2002. Int J Technol Assess Health Care. 2006;22:1925.
14. Draborg, E, Gyrd-Hansen, D. Time-trends in health technology assessments: An analysis of developments in composition of international health technology assessments from 1989 to 2002. Int J Technol Assess Health Care. 2005;21:492498.
15. Framarin, A. First-trimester prenatal screening for Down syndrome and other aneuploidies. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2003.
16. Grunwald, A. The normative basis of (health) technology assessment and the role of ethical expertise. Poeisis Praxis. 2004;2:175193.
17. Ho, C, Banerjee, S, Mensinkai, S. Molecular diagnosis for hereditary cancer predisposing syndromes: Genetic testing and clinical impact. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2003.
18. Hofmann, B. Toward a procedure for integrating moral issues in health technology assessment. Int J Technol Assess Health Care. 2005;21:312318.
19. Hofmann, B. Why ethics should be a part of health technology assessment. I J Technol Assess Health Care. 2008;24:423429.
20. International Network of Agencies for Health Technology Assessment Ethics Working Group. INAHTA's Working Group on Handling Ethical Issues: Final Report; 2005.
21. Jacobs, P, Hailey, D, MacLean, N. Allogeneic stem cell transplantation methods. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR); 2000.
22. Kahn, T, Ninomiya, H. Changing vocabularies: A guide to help bioethics searchers find relevant literature in National Library of Medicine databases using the Medical Subject Headings (MeSH) indexing vocabulary. Kennedy Inst Ethics J. 2003;13:275311.
23. Lehoux, P. The problem of health technology. New York: Routledge; 2006.
24. Lehoux, P, Law, S. Health care technology at home: Issues in organization and delivery in Quebec. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2004.
25. Lehoux, P, Tailliez, S, Denis, JL, Hivon, M. Redefining health technology assessment in Canada: Diversification of products and contextualization of findings. Int J Technol Assess Health Care. 2004;20:325336.
26. Lehoux, P, Williams-Jones, B. Mapping the integration of social and ethical issues in health technology assessment. Int J Technol Assess Health Care. 2007;23:916.
27. McGahan, L, Kakuma, R, Ho, C, et al. BRCA1 and BRCA2 predictive genetic testing for breast and ovarian cancers: A systematic review of clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2006.
28. Menon, D, Topfer, LA. Health technology assessment in Canada. A decade in review. Int J Technol Assess Health Care. 2000;16:896902.
29. Noorani, HZ, McGahan, L. Criteria for selection of adult recipients for heart, cadaveric kidney and liver transplantation. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA); 1999.
30. Palylyk-Colwell, E. CYP450 genotyping for determining drug metabolizer status. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2006.
31. Pineau, G, Moqadem, K, St-Hilaire, C, et al. Telehealth: Clinical guidelines and technological standards for telerehabilitation. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2006.
32. Pineau, G, Moqadem, K, St-Hilaire, C. Telehealth: Clinical guidelines and technological standards for telepsychiatry. Montreal: Agence d'Evaluation des Technologies et des Modes d'Intervention en Sante (AETMIS); 2006.
33. Sandelowski, M. Whatever happened to qualitative description? Res Nursing Health. 2000;23:334340.
34. Scott, A, Alberta Heritage Foundation for Medical R. Living donor liver transplantation in children. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR); 2004.
35. Tran, K, Banerjee, S, Li, H, Noorani, H, Mensinkai, S, Dooley, K. Newborn screening for medium chain acyl~CoA cehydrogenase deficiency using tandem mass spectrometry: Clinical and cost-effectiveness Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2006.
36. Yunkap Kwankam, MM, Hailey, D, Jacobs, P. Cord blood transplantation. HTA 13. Edmonton, AB: Alberta Heritage Foundation for Medical Research (AHFMR); 1998.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed